Health Trials

Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V

ConditionLupus Nephritis
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-100
SponsorNovartis Pharmaceuticals

About this trial

The overall purpose of this two-part study is to evaluate the efficacy, safety and tolerability of iptacopan (LNP023) in addition to standard of care treatment.

Eligibility criteria

Qualifiers

None

Disqualifiers

None

Trial design

Treatments tested in this trial

  • Iptacopan (part 1)
  • Iptacopan (part 2)
  • Placebo + standard of care
  • Iptacopan + placebo

Treatment groups

240 Participants
are divided into 5 treatment groups

Locations

103
Argentina
Novartis Investigative Site2000, RosarioSanta Fe Province, Argentina
Novartis Investigative Site5700, San Luis Argentina
Novartis Investigative SiteS3000EPV, Santa Fe Argentina
Brazil
Novartis Investigative Site40150 150, SalvadorEstado de Bahia, Brazil

Sponsors and collaborators

Novartis Pharmaceuticals

Lead sponsor

Source ClinicalTrials.gov